NCT00885963View on ClinicalTrials.gov

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 1, 2008

Primary Completion Date

August 13, 2013

Study Completion Date

December 23, 2013

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

sapacitabine

twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days

Trial Locations (2)

60612

Rush University Medical Center, Chicago

17033-0850

Penn State Milton S. Hershey Medical Center, Hershey

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY